Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant

Gene Therapy volume 6, pages 1415–1426 (1999)Cite this article

Abstract

With the advent of gene therapy, herpes simplex virus type I (HSV-1) thymidine kinase (TK) has garnered much interest as a suicide gene for cancer ablation. As a means to improve the overall efficacy of the prodrug-gene activation approach, as well as to reduce ganciclovir-mediated toxicity, a large library of mutant thymidine kinases was generated and screened for the ability to enhance in vitro cell sensitivity to the prodrugs, ganciclovir (GCV) and acyclovir (ACV). Enzyme kinetics of one thymidine kinase mutant from this library that contains six amino acid substitutions at or near the active site reveals a distinct mechanism for providing enhanced prodrug-mediated killing in mammalian cells. In in vitro rat C6 cell prodrug sensitivity assays the TK mutant (mutant 30) achieves nanomolar IC50 values with GCV and ACV, in contrast to IC50values of 30 μM and >100 μM, respectively, for wild-type TK. In a mouse xenograft tumor model, growth of mutant 30 expressing tumors is restricted by ganciclovir at a dose at least 10- fold lower than one that impedes growth of wild-type TK-expressing tumors. Furthermore, in the presence of GCV a substantial bystander effect is observable when only 20% of the tumor cells express mutant 30 whereas no restriction in tumor growth is seen in tumors bearing the wild-type TK under the same conditions. The enhanced sensitization to prodrugs conferred by mutant 30 is apparently due to a 35-fold increase in thymidine Km which results in reduced competition between prodrug and thymidine at the active site. This provides mutant 30 a substantial kinetic advantage despite very high Kms for both ganciclovir and acyclovir. Molecular modeling of the mutations within the active site suggests that a tyrosine substitution at alanine 168 (A168) alters thymidine and prodrug interactions by causing catalytically important residues to move. The use of mutant 30 in place of the wild-type TK should provide a more effective gene therapy of cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene Proc Natl Acad Sci USA 1993 90: 7024–7028

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Culver KW et al. In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors Science 1992 256: 9575–9579

    Article  Google Scholar 

  3. Moolten FL, Wells JM . Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors J Natl Cancer Inst 1990 82: 297–300

    Article  CAS  PubMed  Google Scholar 

  4. Reardon JE . Herpes simplex virus type 1 and DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogs. Kinetics of incorporation into DNA and induction of inhibition J Biol Chem 1989 264: 19039–19044

    CAS  PubMed  Google Scholar 

  5. Miller WH, Miller RL . Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase J Biol Chem 1980 255: 7204–7207

    CAS  PubMed  Google Scholar 

  6. Faulds D, Heel RC . Ganciclovir. A review of its antiviral activity, phamacokinetic properties and therapeutic efficacy in cytomegalovirus infections Drugs 1990 39: 597–638

    Article  CAS  PubMed  Google Scholar 

  7. Bi WL, Parysek LM, Warnick R, Stambrook PJ . In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy Hum Gene Ther 1993 4: 725–731

    Article  CAS  PubMed  Google Scholar 

  8. Freeman SM et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 1993 53: 5274–5283

    CAS  PubMed  Google Scholar 

  9. Colombo BM et al. The ‘bystander effect’: association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice Hum Gene Ther 1995 6: 763–772

    Article  CAS  PubMed  Google Scholar 

  10. Dilber MS et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo Cancer Res 1997 57: 1523–1528

    CAS  PubMed  Google Scholar 

  11. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection Proc Natl Acad Sci USA 1994 91: 8185–8189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Black ME, Newcomb TG, Wilson H-MP, Loeb LA . Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy Proc Natl Acad Sci USA 1996 93: 3525–3529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Takamiya Y et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells J Neurosci Res 1992 33: 493–503

    Article  CAS  PubMed  Google Scholar 

  14. Takamiya Y et al. An experimental model of retrovirus gene therapy for malignant brain tumors J Neurosurg 1993 79: 104–110

    Article  CAS  PubMed  Google Scholar 

  15. Chen S-H et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus- mediated gene transfer in vivo Proc Natl Acad Sci USA 1994 91: 3054–3057

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Black ME, Rechtin TM, Drake RR . Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinase J Gen Virol 1996 77: 1521–1527

    Article  CAS  PubMed  Google Scholar 

  17. Munir KM, French DC, Dube DK, Loeb LA . Permissible amino acid substitutions within the putative nucleoside binding site of herpes simplex virus type 1 established by random sequence mutagenesis J Biol Chem 1992 267: 6584–6589

    CAS  PubMed  Google Scholar 

  18. Balzarini J, Bohman C, De Clerq E . Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2 J Biol Chem 1993 268: 6332–6337

    CAS  PubMed  Google Scholar 

  19. Field AK et al. 9- ([2-hydroxy-1-(hydroxymethyl)ethoxy] methyl)guanine: a selective inhibitor of herpes group virus replication Proc Natl Acad Sci USA 1983 80: 4139–4143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Brown DG et al. Crystal structure of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir Nature Struct Biol 1995 2: 876–881

    Article  CAS  PubMed  Google Scholar 

  21. Culver KW et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with herpes simplex thymidine kinase gene/ganciclovir system Hum Gene Ther 1994 5: 334–379

    Article  Google Scholar 

  22. Kun LE, Gajjar A, Muhlbauer M . Sterotactic injection of herpes simplex virus thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors Hum Gene Ther 1995 6: 1231–1255

    Article  CAS  PubMed  Google Scholar 

  23. Alvarez RD, Curiel DT . A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients Hum Gene Ther 1997 8: 598–613

    Google Scholar 

  24. Benda P et al. Differentiated rat glial cell strain in tissue culture Science 1968 161: 370–371

    Article  CAS  PubMed  Google Scholar 

  25. Tiffany-Castiglioni E, Neck KF, Caceci T . Glial culture on artificial capillaries: electron microscopic comparisons of C6 rat glioma cells and rat astroglia J Neurosci Res 1986 16: 387–396

    Article  CAS  PubMed  Google Scholar 

  26. Naus CC, Zhu D, Todd SD, Kidder GM . Characteristics of C6 glioma cells overexpressing a gap junction protein Cell Mol Neurobiol 1992 12: 163–175

    Article  CAS  PubMed  Google Scholar 

  27. Black ME, Rechtin TM, Drake RR . Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinase J Gen Virol 1996 77: 1521–1527

    Article  CAS  PubMed  Google Scholar 

  28. Shewach DS et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells Cancer Gene Ther 1994 1: 107–112

    CAS  PubMed  Google Scholar 

  29. Aghi M et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5′ fluorocytosine/cytosine deaminase gene therapies J Natl Cancer Inst 1998 90: 370–380

    Article  CAS  PubMed  Google Scholar 

  30. Harmenberg J . Intracellular pools of thymidine reduce the antiviral action of acyclovir Intervirology 1983 20: 48–51

    Article  CAS  PubMed  Google Scholar 

  31. Balasubramaniam NK, Veerisetty V, Gentry GA . Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation J Gen Virol 1990 71: 2979–2987

    Article  CAS  PubMed  Google Scholar 

  32. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury (see comments) Science 1994 265: 781–784

    Article  CAS  PubMed  Google Scholar 

  33. Cohen JL et al. Prevenction of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes Blood 1997 89: 4636–4645

    CAS  PubMed  Google Scholar 

  34. Caruso M et al. Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription Virology 1995 206: 495–503

    Article  CAS  PubMed  Google Scholar 

  35. Hruby DE, Ball LA . Control of expresion of the vaccinia virus thymidine kinase gene Virology 1981 113: 594–601

    Article  CAS  PubMed  Google Scholar 

  36. Segel IH . Biochemical Calculations, 2nd edn John Wiley and Sons: New York 1976

    Google Scholar 

  37. Jones TA, Zou J-Y, Cowan SW, Kjeldgaard M . Improved methods for binding protein models in electron density maps and the location of errors in these models Acta Crystallogr 1991 A47: 110–119

    Article  CAS  Google Scholar 

  38. Kraulis P . A program to produce both detailed and schematic plots of protein structure J Appl Cryst 1991 24: 946–950

    Article  Google Scholar 

  39. Merritt EA, Murphy MEP . A program for photorealistic molecular graphics Acta Crystallogr 1994 D50: 869–873

    CAS  Google Scholar 

Download references

Acknowledgements

ETA is supported in part by UW Center grant number P30 ES07033 from the National Institute of Environmental Health Sciences, NIH.

Author information

Authors and Affiliations

  1. Chiroscience R & D, Inc., Bothell, WA, USA

    M S Kokoris, P Sabo & M E Black

  2. Department of Biological Structure, University of Washington, Seattle, WA, USA

    E T Adman

  3. Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, WA, USA

    M E Black

Authors
  1. M S Kokoris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Sabo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E T Adman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M E Black
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kokoris, M., Sabo, P., Adman, E. et al. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther 6, 1415–1426 (1999). https://doi.org/10.1038/sj.gt.3300966

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300966

Keywords

This article is cited by

Search

Advanced search

Quick links